ArticleAnnals of hematology2022

Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).

Hongmei Jing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.